Cleveland Clinic Tumor Boards

Description

This webcast provides expert insight on management strategies for patients with HR-positive breast cancer. Over a review of several cases, the faculty will provide their assessments, as well as additional details on current abemaciclib, ribociclib, palbociclib, and faslodex studies, everolimus and NSABP B-42, breast cancer index and other biomarkers.

Learning Objectives

Identify the current standard of care for endocrine therapy in patients with hormone receptor-positive advanced breast cancer

Discuss key results of clinical trials of fulvestrant, alone and in combination regimens, for treatment of HR-positive disease

State the mechanism of action of CDK4/6 inhibitors and rationale for their use in HR-positive advanced breast cancer

Assess the efficacy and safety of CDK4/6 inhibitors observed in recent clinical trials in women with HR-positive, HER2-negative breast cancer and its potential to overcome endocrine resistance

Explain the rationale for use of mTOR inhibitors for treatment of patients with HR-positive advanced breast cancer, and summarize recent clinical trial data supporting the efficacy of such agents in this patient population

Target Audience

This activity is designed for health care practitioners including medical oncologists, surgical oncologists and general surgeons, radiation oncologists, radiologists, pathologists, and other health care professionals who manage patients with breast cancer.

Accreditation

The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 1.25AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

CME Disclaimer

The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.

Disclosures

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated that they may have a relationship, which in the context of their presentation, could be perceived as a potential conflict of interest: